Molecular epidemiology and antifungal susceptibilities of Cryptococcus species isolates from HIV and non-HIV patients in Southwest China

Eur J Clin Microbiol Infect Dis. 2021 Feb;40(2):287-295. doi: 10.1007/s10096-020-04013-4. Epub 2020 Sep 7.

Abstract

To investigated the molecular epidemiology and in vitro antifungal susceptibility of Cryptococcus isolates from West China Hospital from HIV and non-HIV patients between 2009 and 2015. A total of 132 C. neoformans and C. gattii were subjected to antifungal susceptibility testing by E-test method. Among the 132 isolates, 42 C. neoformans and C. gattii were analyzed by mating type and URA5-RFLP. A total of 113 C. neoformans and C. gattii were subjected to multi-locus sequence typing (MLST). MLST results revealed that ST5 was the major molecular type. The wild-type (WT) phenotype was seen in 91.5-100% of C. neoformans isolates for amphotericin B, 5-flucytosine, fluconazole, and voriconazole. However, 72.3% (94/130) of C. neoformans isolates were non-wild-type (non-WT) to itraconazole by E-test method. In the sixth study year, the geometric mean, MIC50 and MIC90 of fluconazole were the highest (P < 0.001). Among 132 patients. 52 were coinfected with HIV and 80 were HIV-negative. Isolates from HIV and non-HIV patients showed no differences in susceptibility to amphotericin B (P = 0.544), 5-flucytosine (P = 0.063), fluconazole (P = 0.570), voriconazole (P = 0.542), and itraconazole (P = 0.787). Our study showed that Cryptococcus in southwest China showed a low degree of genetic diversity. The increased MIC values of fluconazole are noted. Cryptococcus isolates from HIV and non-HIV patients have shown no differences in susceptibility to five antifungal agents.

Keywords: Antifungal susceptibilities; Cryptococcus; HIV; Molecular epidemiology; Southwest China.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antifungal Agents / pharmacology*
  • China / epidemiology
  • Cryptococcosis* / epidemiology
  • Cryptococcosis* / microbiology
  • Cryptococcus gattii* / drug effects
  • Cryptococcus gattii* / genetics
  • Cryptococcus neoformans* / drug effects
  • Cryptococcus neoformans* / genetics
  • Drug Resistance, Fungal / genetics*
  • Female
  • Genetic Variation
  • HIV Infections / epidemiology*
  • Humans
  • Male
  • Middle Aged
  • Young Adult

Substances

  • Antifungal Agents